Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only the single pregnancy discontinuation statement is supported by the provided Diovan label excerpts. Multiple other claims made in the input are not supported or verified against the supplied label text, and no label-based evidence is provided for them.
Category Scores
Accurate Statements
When pregnancy is detected, discontinue Diovan (valsartan) as soon as possible.
Supported by provided label excerpts: Warnings and Precautions (5.1) and Use in Specific Populations (8.1).
Unsupported Statements
Valsartan is an angiotensin II receptor blocker used to treat high blood pressure.
No supporting label text for indication was supplied in the prompt for evaluation.
The patent for Valsartan expired in 2012 in the United States.
Patent/exclusivity timeline claims are not addressed in the provided prescribing information excerpts.
Initially, the Valsartan patent was set to expire in 2010.
Patent timeline details are not supported by the provided label excerpts.
Novartis extended the Valsartan patent lifespan by an additional six months.
Not supported by the provided prescribing information excerpts.
As a result of Valsartan patent expiry, generic versions of valsartan have been approved and are available on the U.S. market.
Generic approval/market availability is not discussed in the provided prescribing information excerpts.
Numerous generic versions of Valsartan have been approved for sale in the U.S. since the patent expiry.
Generic availability/number of manufacturers is not addressed in the provided label excerpts.
The generic version of Valsartan contains the same active ingredient as the branded version.
No label text was supplied to verify this claim.
The generic version of Valsartan contains the same quantity of the active ingredient as the branded version.
No label text was supplied to verify this claim.
Clinical studies have shown generics of Valsartan are equivalent in efficacy to the branded version.
No label text was supplied to verify this claim.
Clinical studies have shown generics of Valsartan are equivalent in safety to the branded version.
No label text was supplied to verify this claim.
Valsartan can cause decreased renal function.
No label excerpt supporting this specific adverse effect was supplied for evaluation.
Valsartan can cause elevated potassium levels.
No label excerpt supporting this specific adverse effect was supplied for evaluation.
Valsartan can cause angioedema.
No label excerpt supporting this specific adverse effect was supplied for evaluation.
Several pharmaceutical companies make generic versions of Valsartan, including Teva, Mylan, and Sandoz.
Manufacturer lists for generics are not addressed in the provided prescribing information excerpts.
The exclusivity agreement for Valsartan expired in 2012.
Exclusivity agreement timeline is not addressed in the provided prescribing information excerpts.
There is no further information suggesting extensions to Valsartan exclusivity.
Not supported by the provided prescribing information excerpts.
Contradictions
Important Omissions
For claims beyond pregnancy discontinuation (e.g., renal function decline, hyperkalemia, angioedema, and indication), the response did not provide any supporting citations or label excerpts from the FDA-approved prescribing information.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While the only label-supported safety-related claim in the provided material (pregnancy discontinuation) is accurate, many additional claims include safety and market/patent assertions without label support. Lack of label support prevents validation and could lead to inaccurate information use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Most claims are not supported by the provided FDA prescribing information excerpts; only the pregnancy discontinuation statement is verifiably supported.
Suggested Improvement
Restrict label-based statements to those supported by the supplied Diovan prescribing information text (e.g., Warnings and Precautions 5.1 and Use in Specific Populations 8.1), and provide specific label citations for any additional clinical safety/adverse reaction or indication claims.